Bevespi Aerosphere ([formoterol + glycopyrrolate]; AstraZeneca) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist (LABA) formoterol and the long-acting muscarinic antagonist (LAMA) glycopyrrolate, delivered via a pressurized metered dose inhaler.
While Bevespi Aerosphere demonstrated statistically significant improvements in trough forced expiratory volume in one second (FEV1) compared to its individual components and placebo in its Phase III PINNACLE program, pulmonologists are unconvinced about its role in symptom improvement. Datamonitor Healthcare expects Bevespi Aerosphere to have significantly lower uptake compared to the most promising LABA/LAMA combinations, Utibron ([indacaterol + glycopyrrolate]; Sunovion/Novartis/Pfizer/Sosei) and Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim), despite AstraZeneca’s experience in the respiratory market and strong marketing capabilities.
LIST OF FIGURES
12 Figure 1: Bevespi Aerosphere for COPD – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Bevespi Aerosphere for COPD
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Bevespi Aerosphere for COPD
16 Figure 4: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Bevespi Aerosphere drug profile
7 Table 2: Bevespi Aerosphere Phase III data in COPD
10 Table 3: Other Bevespi Aerosphere Phase III trial data
11 Table 4: Bevespi Aerosphere ongoing Phase III trial in COPD
17 Table 5: Bevespi Aerosphere sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.